Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 4, 2012, Pages 603-609

  Addeo, Raffaele ^a   Sperlongano, Pasquale ^b   Montella, Liliana ^a   Vincenzi, Bruno ^c   Carraturo, Marco ^d   Iodice, Patrizia ^a   Russo, Paola ^a   Parlato, Ciro ^b   Salzano, Antonio ^e   Cennamo, Gregorio ^a   Lombardi, Angela ^b   Sperlongano, Rossella ^b   Del Prete, Salvatore ^a   Caraglia, Michele ^b  

^a SAN GIOVANNI DI DIO HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d ASL Napoli   (Italy)

^e S Giovanni di Dio Hospital   (Italy)

Author keywords

Brain metastasis; Breast cancer; Metastatic breast cancer; Metronomic chemotherapy; Newly diagnosed brain metastasis; Whole brain radiotherapy

Indexed keywords

NAVELBINE; TEMOZOLOMIDE; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; CANCER PROGNOSIS; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FUNCTIONAL ASSESSMENT; HAND FOOT SYNDROME; HEADACHE; HUMAN; LOW DRUG DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SENSORY NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DACARBAZINE; FEMALE; HUMANS; MIDDLE AGED; QUALITY OF LIFE; VINBLASTINE;

EID: 84867574450     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1945-4     Document Type: Article

References (32)

1. Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22:3608-3617
2. Eichler AF, Loeffler JS (2007) Multidisciplinary management of brain metastases. Oncologist 12:884-898
3. Ewend MG, Elbabaa S, Carey LA (2005) Current treatment paradigms for the management of patients with brain metastases. Neurosurgery 57(5 Suppl):S66-S77 (discussion S1-4)
4. Platta CS, Khuntia D, Mehta MP, Suh JH (2010) Current treatment strategies for brain metastasis and complications from therapeutic techniques: a review of current literature. Am J Clin Oncol 33(4):398-407
5. Addeo R, Caraglia M (2011) The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer? Expert Rev Anticancer Ther 11(2):139-142
6. Langer CJ, Mehta MP (2005) Current management of brain metastases, with a focus on systemic options. J Clin Oncol 23:6207-6219
7. Patel M, McCully C, Godwin K, Balis FM (2003) Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol 61(3):203-207
8. Trudeau ME, Crump M, Charpentier D et al (2006) Temozolomide in metastatic breast cancer (MBC): a phase II trial of the national cancer institute of Canada-clinical trials group (NCICCTG). Ann Oncol 17:952-995
9. Antonadou D, Paraskevaidis M, Sarris G et al (2002) Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 20:3644-3650
10. Addeo R, Caraglia M, Faiola V et al (2007) Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life. BMC Cancer 7:18
11. Addeo R, De Rosa C, Faiola V et al (2008) Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for non small cell lung cancer and breast cancer patients with brain metastases. Cancer 113(9):2524-2531
12. Fumoleau P, Delgado FM, Delozier T et al (1993) Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J ClinOncol 11(7):1245-1252
13. Marty M, Fumoleau P, Adenis A et al (2001) Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 12(11):1643-1649
14. Freyer G, Delozier T, Lichinister M et al (2003) Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 21(1):35-40
15. Kobayashi S, Sakai T, Dalrymple PD, Wood SG, Chasseaud LF (1993) Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. Arzneimittelforschung 43:1367-1377
16. Donadio M, Ardine M, Berruti A et al (2003) Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study. Cancer Chemother Pharmacol 52:147-152
17. Colleoni M, Graiff C, Nelli P et al (1997) Activity of combination chemotherapy in brain metastases from breast and lung adenocarcinoma. Am J Clin Oncol 20:303-307
18. Gebbia V, Puozzo C (2005) Oral versus intravenous vinorelbine: clinical safety profile. Expert Opin Drug Saf 4:915-928
19. Addeo R, Sgambato A, Cennamo G et al (2010) Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer. Clin Breast Cancer 10(4):301-306
20. Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G (1997) Reliability and validity of the functional assessment of cancer therapy-breast quality-oflife instrument. J Clin Oncol 15(3):974-986
21. Simon R (1989) Optimal 2-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
22. Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
23. Mahmoud-Ahmed AS, Suh JH, Lee S-Y et al (2002) Results of whole brain radiotherapy in patients with brain metastases from breast cancer: a retrospective study. Int J Radiat Oncol Biol Phys 54:810-817
24. Kienast Y, Winkler F (2010) Therapy and prophylaxis of brain metastases. Expert Rev Anticancer Ther 10(11):1763-1777
25. Addeo R, Caraglia M (2011) Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera? Expert Opin Investig Drugs 20(7):881-895
26. Tosoni A, Franceschi E, Brandes AA (2008) Chemotherapy in breast cancer patients with brain metastases: have new chemotherapic agents changed the clinical outcome? Crit Rev Oncol Hematol 68:212-221
27. Trudeau ME, Crump M, Charpentier D et al (2006) Temozolomide in metastatic breast cancer (MBC): a phase II trial of the national cancer institute of Canada-clinical trials group (NCICCTG). Ann Oncol 17:952-956
28. Caraglia M, Addeo R, Costanzo R, Montella L, Faiola V, Marra M, Abbruzzese A, Palmieri G, Budillon A, Grillone F, Venuta S, Tagliaferri P, Del Prete S (2006) Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. Cancer Chemother Pharmacol 57(1):34-39
29. Iwamoto FM, Omuro AM, Raizer JJ, Nolan CP, Hormigo A, Lassman AB, Gavrilovic IT, Abrey LE (2008) A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 87(1):85-90
30. Omuro AM, Raizer JJ, Demopoulos A, Malkin MG, Abrey LE (2006) Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial. J Neurooncol 78:277-280
31. Gerstner ER, Fine RL (2007) Increased permeability of the bloodbrain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 25(16):2306-2312
32. Siena S, Crino L, Danova M, Del Prete S, Cascinu S, Salvagni S, Schiavetto I, Vitali M, Bajetta E (2010) Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. Ann Oncol 21(3):655-661